nVerses Capital’s Roivant Sciences ROIV Stock Holding History

nVerses Capital’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,200	Closed	-$33.8K	–	1338
2024 Q2	$33.8K	Buy	+3,200	New	+$35.1K	0.02%	667

Other funds holding ROIV

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

nVerses Capital's ROIV Position: Q3 2024 in Review

nVerses Capital sold out of Roivant Sciences (ROIV) in Q3 2024, closing a stake of 3,200 shares — an estimated $33.8K sold.

nVerses Capital first reported a position in ROIV in Q2 2024 and held it in 1 quarter. The position peaked at $33.8K in Q2 2024. 293 funds tracked by Wall St. Rank hold ROIV as of Q3 2024.

nVerses Capital reported no remaining Roivant Sciences position as of Q3 2024 after selling out during the quarter.
nVerses Capital sold 3,200 Roivant Sciences shares in Q3 2024, an estimated $33.8K.
nVerses Capital first reported a position in Roivant Sciences in Q2 2024 and held it in 1 quarter.
nVerses Capital's Roivant Sciences position peaked at $33.8K in Q2 2024.
293 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.